For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Anti-Aging & Longevity · Comparison

GDF-11 (Growth Differentiation Factor 11) vs GHK-Cu

A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GDF-11 (Growth Differentiation Factor 11)GHK-Cu
CategoryAnti-Aging & LongevityAnti-Aging & Longevity
Also known asGDF11, Bone Morphogenetic Protein 11, BMP-11, young blood factorCopper Peptide GHK-Cu, Glycyl-L-histidyl-L-lysine copper, Copper Tripeptide-1
EvidenceResearch-stageResearch-stage
Dosing range0.1mg/kg–1mg/kg mg/kg, every 3–7 days (SC); research protocols vary widely1mg–3mg mg, daily to every other day (injectable); twice daily (topical)
AdministrationSubcutaneous injection, Intravenous (research)Subcutaneous injection, Topical application (cream, serum — most common consumer use), Intradermal injection (skincare clinics)
Key side effectsCardiac hypertrophy (at pharmacologic doses — the key safety concern), Muscle wasting and weight loss, Reproductive effects (GDF-11 inhibits spermatogenesis and folliculogenesis), Cachexia-like syndrome at high dosesInjection site redness (transient), Mild skin irritation with topical (typically resolves with reduced frequency), Rarely reported: metallic taste (with injectable use at higher doses)
Cited sources2 references4 references

Key differences

  • Administration: GDF-11 (Growth Differentiation Factor 11) — Subcutaneous injection, Intravenous (research); GHK-Cu — Subcutaneous injection, Topical application (cream, serum — most common consumer use), Intradermal injection (skincare clinics).
  • Dosing units differ: GDF-11 (Growth Differentiation Factor 11) is dosed in mg/kg, GHK-Cu in mg — they operate at different scales.
  • Frequency: GDF-11 (Growth Differentiation Factor 11) is typically every 3–7 days (SC); research protocols vary widely; GHK-Cu is daily to every other day (injectable); twice daily (topical).
  • Research depth: this profile cites 2 sources for GDF-11 (Growth Differentiation Factor 11) vs 4 for GHK-Cu.

How each works

GDF-11 (Growth Differentiation Factor 11)

The 2013–2014 parabiosis studies from Amy Wagers' lab at Harvard proposed GDF-11 as the primary rejuvenating factor in young blood. However, subsequent work by Lee and others showed that purified recombinant GDF-11 at pharmacologic doses caused cardiac hypertrophy, muscle atrophy, and weight loss — opposite of the proposed rejuvenating effects. The field now views GDF-11 as highly dose-sensitive with a narrow therapeutic window, if one exists at all.

GHK-Cu

GHK-Cu has been studied for its ability to stimulate collagen, elastin, and glycosaminoglycan synthesis, promote wound healing, and exhibit antioxidant and anti-inflammatory effects. Gene-expression work by Pickart and colleagues found GHK altered expression (>50% up or down) in roughly 32% of assayed human genes — the basis of the widely-cited '~4,000 genes' figure. Its evidence is strongest for in-vitro and topical/cosmetic use; robust human trials of injectable/systemic GHK-Cu are lacking.

Read the full GDF-11 (Growth Differentiation Factor 11) profileRead the full GHK-Cu profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.